TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Preferred suturing method
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Improvement in IIEF-EF scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of ursodeoxycholic acid in bile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of a mineralized barrier
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apical closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronal or radicular fractures
Endpoint domain: Adverse events/effects
Primary endpoint: Seroresponse (≥ 4‐fold rise in HPIV3 antibody from baseline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vaccine virus shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Levels of markers of bone physiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Ro 45‐2081
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aggressive Behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Somatic Complaints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conduct Problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: F-scores for Outcome Measure sentences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median bFFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median time for PSA values >2.0 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum total protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal oxygen consumption (VO2 max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vertical jump height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: PASI75 total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Median time to 75% improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PRTEE disability scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Doppler grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suppressed pigmentation after UVB irradiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Ocular or local adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Lower sugar-sweetened beverage purchases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dressing frequency
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety class after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: duration of delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total outpatient visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: IBD-related school absence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Total intravenous morphine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe rash (grade 3)
Endpoint domain: Adverse events/effects
Primary endpoint: BIS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with the leaflet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Grade 3 to 4 mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 4 granulocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiovascular death, spontaneous myocardial infarction or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of xerostomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proteinuria decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total bacteria in plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral streptococci in plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ATP bioluminescence values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiographic progression of joint damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Health status improvement (KCCQ-OS score)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Health status improvement (SF-36 physical summary scale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improved cardiac function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fewer healthcare contacts
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fewer emergency room visits and admissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: IPSS-QoL
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: OABSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colorectal cancer (CRC) incidence
Endpoint domain: Mortality/survival
Primary endpoint: Pain at home
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: summed recall score on the Buschke selective reminding test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in digit symbol test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent heavy drinking days (PHDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum lutein concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual sensitivities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in apnea hypopnea index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete resolution of pediatric OSAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in cerebral blood flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean rank of modified ranking scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean change of the Barthel Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Shortness of breath at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Capillary oxygen tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum 25-hydroxyvitamin D3 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CD8(+) T-cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4(+) T-cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Flow in the IMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Flow in the radial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: s-cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Worsening of suicidal ideation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of MI, unstable angina, cardiac arrest, and cardiac death rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Net clinical benefit events (all strokes, systemic embolism, MI, pulmonary embolism, major bleeding, and all-cause death)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overnight urinary cortisol/creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adherence to dietary recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma peak concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between decision model and surgeon's initial plan
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Surgeon comfort level (PDPI score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in left ventricular diastolic functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Achievement of JAS LDL-C goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of BiV ATP to terminate all VT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: wound effusion score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of kinetic properties of THP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in menopausal symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lowering total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in bone resorption marker (deoxypyridinoline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fractional clearance of IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fractional clearance of albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improved/prolonged high quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: nonadherence to endocrine therapy (ET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage reduction of depigmented area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional movement improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait ability improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean haemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: sustained response (SR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of moderate-to-severe depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blood glycaemic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite score of gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Healing abnormalities rate
Endpoint domain: Adverse events/effects
Primary endpoint: BII (BPH Impact Index)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anastomotic leak rate
Endpoint domain: Adverse events/effects
Primary endpoint: 9-year patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Healing rate of feet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: participation
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: satisfaction
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: knowledge acquisition
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Volume of the ventral RAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of tumor within preserved ventral RAS
Endpoint domain: Adverse events/effects
Primary endpoint: Combined endpoint of cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Improvement on trained items
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum beta‐hCG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ang‐2 serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rates of osseointegrated implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of symptoms as assessed by CBCL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of symptoms as assessed by CGI-P (emotional liability)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival Index (GI) and Bleeding on Probing (BOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of antibiotic prophylaxis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of low severity adverse drug reactions (ADR)
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative infection rates
Endpoint domain: Adverse events/effects
Primary endpoint: Aortic waveform parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Global response assessment improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Concordance between mMT parameters and neuropsychological diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for discrimination of AD from MCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for discrimination of AD from MCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper-extremity function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of intra-aortic balloon pump use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: lipoprotein lipase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: circulating plasma non-esterified fatty acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PT score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Riboflavin deficiency prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Iron deficiency anemia prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infarct size by creatine kinase‐MB area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ninety-day mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: radiologic progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Variability of exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental component score (MCS) improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anti-factor Xa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clotting times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: perceived exertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: attendance of rehabilitation programme
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: satisfaction with early education
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Transient adverse events (headache and nausea)
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma PAA:PAGN ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OMI success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain during OMI placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain during OMI removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in energy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: EFA (Effective Fungicidal Activity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ten-week mortality
Endpoint domain: Mortality/survival
Primary endpoint: dorsiflexion range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrinkle score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Linear shrinkage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: subjectively perceived fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: neck pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal and explosive strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall ICD therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appropriate ICD therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactate level normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Health utility (EQ-5D scores)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stillbirth rate
Endpoint domain: Mortality/survival
Primary endpoint: HBeAg seroconversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of home visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Patient satisfaction with Telehealth service
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: immediate hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPR quality index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative opioid use during the initial 24-h period after extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of small MFs within regeneration units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: solitary MFs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: NIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neonatal umbilical arterial base deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neonatal umbilical arterial pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Homeostasis Model Assessment‐Insulin Resistance Index (HOMA‐IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting leptin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum lidocaine absorption levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse reactions to OTC preparations
Endpoint domain: Adverse events/effects
Primary endpoint: Serum TC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: DSH repetition rate
Endpoint domain: Mortality/survival
Primary endpoint: Food anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Methamphetamine craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported stimulant use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of diverticulitis episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Acute postoperative neurological deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Good outcome at 3 months (GOS score of 1)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of patients with psychological stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of sICAM-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in severity of nausea or vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF HVA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes